Prelude Therapeutics Inc Quarterly Assets, Current in USD from Q4 2019 to Q2 2025

Taxonomy & unit
us-gaap: USD
Description
Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.
Summary
Prelude Therapeutics Inc quarterly Assets, Current history and growth rate from Q4 2019 to Q2 2025.
  • Prelude Therapeutics Inc Assets, Current for the quarter ending June 30, 2025 was $76.9M, a 57.9% decline year-over-year.
Assets, Current, Quarterly (USD)
Assets, Current, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q2 2025 $76.9M -$106M -57.9% Jun 30, 2025 10-Q 2025-08-14
Q1 2025 $102M -$103M -50.1% Mar 31, 2025 10-Q 2025-05-06
Q4 2024 $136M -$99.7M -42.3% Dec 31, 2024 10-Q 2025-08-14
Q3 2024 $156M -$78.5M -33.4% Sep 30, 2024 10-Q 2024-11-06
Q2 2024 $183M -$77.5M -29.8% Jun 30, 2024 10-Q 2024-08-12
Q1 2024 $205M +$30.1M +17.2% Mar 31, 2024 10-Q 2024-05-07
Q4 2023 $236M +$31.2M +15.3% Dec 31, 2023 10-K 2025-03-10
Q3 2023 $235M +$8.02M +3.54% Sep 30, 2023 10-Q 2023-11-01
Q2 2023 $260M +$11.6M +4.66% Jun 30, 2023 10-Q 2023-08-03
Q1 2023 $175M -$94.7M -35.1% Mar 31, 2023 10-Q 2023-05-08
Q4 2022 $204M -$90.7M -30.7% Dec 31, 2022 10-K 2024-02-15
Q3 2022 $227M -$99M -30.4% Sep 30, 2022 10-Q 2022-11-14
Q2 2022 $249M -$96M -27.8% Jun 30, 2022 10-Q 2022-08-09
Q1 2022 $270M -$95M -26% Mar 31, 2022 10-Q 2022-05-10
Q4 2021 $295M +$74.3M +33.7% Dec 31, 2021 10-K 2023-03-15
Q3 2021 $326M +$87.8M +36.9% Sep 30, 2021 10-Q 2021-11-12
Q2 2021 $345M Jun 30, 2021 10-Q 2021-08-12
Q1 2021 $365M Mar 31, 2021 10-Q 2021-05-11
Q4 2020 $221M +$201M +992% Dec 31, 2020 10-K 2022-03-17
Q3 2020 $238M Sep 30, 2020 10-Q 2020-11-10
Q4 2019 $20.2M Dec 31, 2019 10-K 2021-03-16
* An asterisk sign (*) next to the value indicates that the value is likely invalid.